Top Markets
Coin of the day
Abliva AB (publ) Abliva AB (publ)

Abliva AB (publ)

ABLI
Rang in Aktien #22998
Abliva AB (publ), a Swedish biopharmaceutical company founded in Lund in 2000,... Abliva AB (publ), a Swedish biopharmaceutical company founded in Lund in 2000, focuses on developing innovative therapeutic solutions for primary mitochondrial diseases. Its pipeline includes KL1333, currently in Phase 2/3 clinical trials for the long-term management of these conditions, and NV354, which is preparing for clinical studies targeting primary mitochondrial diseases specifically linked to Complex I deficiency. The company is also advancing NeuroSTAT through a Phase 1b/2a clinical study for the treatment of traumatic brain injury. Abliva maintains strategic partnerships with entities such as Isomerase, Yungjin Pharm, the University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The firm rebranded as Abliva AB (publ) in May 2020, having previously been known as NeuroVive Pharmaceutical AB (publ).
Aktienkurs
$0.04959193
Zuletzt synchronisiert: 2025-03-17
Marktkapitalisierung
$79.94M
Veränderung (1 Tag)
13.49%
Veränderung (1 Jahr)
0.00%
Land
SE
Handel Abliva AB (publ) (ABLI)

Kategorie

Aktien-Split-Historie für Abliva AB (publ) (ABLI)
Die Aktie Abliva AB (publ) (Symbol: ABLI) durchlief insgesamt 0 Aktiensplits.
Der letzte Aktiensplit fand am Aug 22, 2026 statt.
Eine ABLI-Aktie, die vor dem Aug 22, 2026 gekauft wurde, entspricht heute 0 ABLI-Aktien.
Liste der Aktiensplits
Jahr Aktien-Split Multiplikator Kumulierter Multiplikator
Nicht genügend Daten für die angegebenen Daten.
Aktiensplits ähnlicher Unternehmen oder Wettbewerber
Unternehmen Anzahl der Aktiensplits Kumulierter Multiplikator Land
1 x2
US
0 -
NL
0 -
US
1 x3
AU
0 -
CH